Synosia reports early clinical data for Parkinson's candidate
This article was originally published in Scrip
Executive Summary
Synosia Therapeutics has reported some potentially positive interim results from a Phase IIa study investigating its experimental adenosine 2a (A2a) receptor antagonist SYN-115 as an adjunctive therapy to levodopa in Parkinson's disease.